Encouraging results from clinical Phase I study of Oncoral presented in a new publication

2018-11-13
Download
In continuation of the previously published poster presentation at ESMO in Munich, 19-23 October 2018, Ascelia Pharma has announced the encouraging Phase I results in a new publication titled Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

The publication, which is available on pubmed.gov, contains data from a dose escalation study in adult patients with solid tumors to assess safety, tolerability and pharmacokinetics of Oncoral, an oral irinotecan formulation, given as single agent.

The data demonstrated that Oncoral was well tolerated; side effects were generally mild to moderate, manageable and similar in type to those observed with intravenous irinotecan.

Furthermore:

  • In total 25 patients were included across four cohorts. The age range was 51-82 years and the majority of patients had Cholangiocarcinoma, Colon, Pancreas or Prostate as primary cancer
  • Hematological toxicities were few and all were mild to moderate
  • Pharmacokinetic (PK) data showed consistent daily exposures during treatment at days 1 and 14 with no drug accumulation
  • The interpatient variability of the active metabolite, SN-38, was in the same range as after infusion of irinotecan
  • Consequently, in this heavily pre-treated patient population, Oncoral indicated activity even among patients previously treated with irinotecan

”These clinical data on Oncoral are encouraging since they indicate a future potential safe and efficient oral administration route of irinotecan. We look forward to presenting results from further clinical investigations next year where Oncoral is administered in combination with capecitabine, thus enabling a potential attractive all-oral chemotherapy combination”, said Carl Bjartmar, MD, PhD, Chief Medical Officer of Ascelia Pharma.

For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110

2021-04-09

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma AB (”Ascelia Pharma”) has resolved to issue and immediately thereafter repurchase 397,641 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020.
2021-03-31

NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797 (“Ascelia Pharma”), are hereby invited to the annual general meeting (Sw. årsstämma) to be held on Wednesday 5 May 2021.
2021-03-31

Number of shares and votes in Ascelia Pharma AB

During March 2021, the number of shares and votes in Ascelia Pharma AB have increased by 481,573 due to the exercise of in total 481,573 warrants under the company’s incentive program.